The unfinished business of primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
In nearly every multifactorial human disease, there are three periods that characterize our understanding and definition. First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period as information is obtained that redefines and expands basic and clinical knowledge that lacks the final and important area of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vigorous definition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago and for the first 40 or so years, the primary research efforts were directed at clinical definitions and pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial antibodies. These efforts have greatly helped in our understanding of not only the effector mechanisms of disease, but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful translation for specific therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Self-citationPrognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 2×
“This was of particular interest in the comparison with established prognostic scores such as the Mayo score [23].”
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 1×
“Indeed, a complete biochemical response to UDCA as normalization of alkaline phosphatase levels is suggested as a major determinant of UDCA effectiveness on disease progression (31).”
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Self-citationGershwin, M. E., Mackay, I. R., Sturgess, A., & Coppel, R. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3525 · Cited by 557
Self-citationSEROLOGICAL TESTS IN DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS
WALKER, J. (1965) · The Lancet · doi:10.1016/s0140-6736(65)91372-3 · Cited by 507 · cited 1×
“Phase 1 Earlier breakthrough Proof of AMA specificity [94] Established diagnostic criteria [95] Phase 2 Minimizing AMA-negative Use of recombinant antigens [96] Use of multiplex AMA tests [12] Phase 3 What is next? 100% specific histology 100% sensitive AMA tests PBC-diagnostic ANA”
Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment
Selmi, C., Mayo, M. J., Bach, N., Ishibashi, H., Invernizzi, P., Gish, R. G., Gordon, S. C., Wright, H. I., Zweiban, B., Podda, M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.005 · Cited by 480 · cited 1×
“Phase 1 Earlier breakthrough Familial PBC [4] Twin concordance [98] Risk factors [9] Phase 2 Later developments HLA/non-HLA associations [99] X chromosome defects [100] Bacterial candidates [101] Xenobiotic reactivity [56] Phase 3 What is next? Genome-wide association studies Spontaneous animal models Epigenetic studi…”
Self-citationDrug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“UDCA mechanism of action in PBC remains incompletely understood but it has been hypothesized that it is based on several factors, including stimulation of impaired secretion of the bile-acid pool, reduction in proinflammatory cytokines, effects on apoptosis and on vasoactive mediators (27-29).”
Epidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Ranke, M. B., & Saenger, P. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05487-3 · Cited by 345
Cited by
Natural killer cells regulate T cell immune responses in primary biliary cirrhosis
Shimoda, S., Hisamoto, S., Harada, K., Iwasaka, S., Chong, Y., Nakamura, M., Bekki, Y., Yoshizumi, T., Shirabe, K., Ikegami, T., et al. (2015) · Hepatology · doi:10.1002/hep.28122 · Cited by 82
Self-citationBizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
“hepatic bile ducts are targeted by an immune-mediated injury, ultimately leading to liver fibrosis and cirrhosis [1].”
BackgroundSelf-citationTerziroli Beretta-Piccoli, B., Mieli-Vergani, G., & Vergani, D. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.004 · Cited by 61
Metadata
- Authors
- Selmi, C., Zuin, M., & Gershwin, M. E.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 49
- Issue
- 3
- Pages
- 451-460
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1989400873
- Cited by
- 50
- References
- 26
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The unfinished business of primary biliary cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhep.2008.06.006
- The paper
- Selmi, C., Zuin, M., & Gershwin, M. E. (2008). The unfinished business of primary biliary cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2008.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.